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Abstract
Objective To test the hypothesis that fusidic acid
would not increase the treatment effect of disinfecting
with povidone›iodine alone in children with impetigo.
Design Randomised placebo controlled trial.
Setting General practices in Greater Rotterdam.
Participants 184 children aged 0›12 years with
impetigo.
Main outcome measures Clinical cure and bacterial
cure after one week.
Results After one week of treatment 55% of the
patients in the fusidic acid group were clinically cured
compared with 13% in the placebo group (odds ratio
12.6, 95% confidence interval 5.0 to 31.5, number
needed to treat 2.3). After two weeks and four weeks
the differences in cure rates between the two groups
had become smaller. More children in the placebo
group were non›compliant (12 v 5) and received extra
antibiotic treatment (11 v 3), and more children in the
placebo group reported adverse effects (19 v 7).
Staphylococcus aureus was found in 96% of the positive
cultures; no strains were resistant to fusidic acid.
Conclusions Fusidic acid is much more effective than
placebo (when both are given in combination with
povidone›iodine shampoo) in the treatment of
impetigo. Because of the low rate of cure and high
rate of adverse events in the placebo group, the value
of povidone›iodine in impetigo can be questioned.
Introduction
Impetigo is the most common skin infection in
children; it is caused mainly by Staphylococcus aureus
and sometimes by Streptococcus pyogenes (group A).1 2
Because of the supposedly benign spontaneous course
of impetigo, some authors suggest that an expectant
attitude with disinfection but no antibiotic treatment
would suffice in mild cases.3–5 Antiseptic treatment with
chlorhexidine or povidone›iodine is often advocated as
a useful adjunct to antibiotic treatment.3 5
Immediate antibiotic treatment is advised for most
cases of impetigo, to achieve a quick cure and prevent
spread of the infection to other children.4–6 Oral
antibiotic treatment has long been the first choice,
because of better treatment results and because topical
antibiotic treatment is more likely to induce sensitisa›
tion and bacterial resistance.7 In recent years, however,
the resistance of staphylococci to oral antibiotics such
as erythromycin has increased dramatically.1 8–11 At the
same time, topical antibiotic treatment with mupirocin
has been shown to give results equal to or even better
than oral treatment.1 9 12 13 In general, children comply
better with topically administered treatment than with
oral treatment,13 and fewer systemic side effects occur.8
Fusidic acid is an antibiotic that has been available
for a long time and is mainly used topically.14 It is rec›
ommended as the first choice topical antibiotic in the
Dutch College of General Practitioners’ guidelines on
the treatment of impetigo.3 Some authors discourage
the topical use of fusidic acid because of its value in
systemic treatment,5 15 although other authors recom›
mend that mupirocin should be reserved for treatment
of nasal carriage of S aureus in specific groups of
patients.3 16 A recent meta›analysis of three randomised
trials found the overall clinical effect of fusidic acid
cream in patients with impetigo to be equal to that of
mupirocin,17 but the effectiveness of fusidic acid has
never been assessed in comparison with placebo. The
cost of fusidic acid compares favourably with that of
mupirocin.
We compared the effectiveness of fusidic acid
cream and placebo cream, both added to a disinfecting
treatment with povidone›iodine, in the treatment of
impetigo in children. Our hypothesis was that fusidic
acid cream would not improve the treatment effect of
povidone›iodine.
Methods
Participants
We asked general practitioners in the Greater
Rotterdam area to report patients aged 0›12 years with
non›bullous impetigo presenting at their surgery. We
excluded patients who were immunocompromised;
patients with extensive lesions (estimated area more
than 5% of the total skin surface), infections of deeper
skin structure, temperature > 38.5°C, hypersensitivity
to povidone›iodine, or hyperthyroidism; patients who
had used topical or systemic antibiotics in the previous
48 hours; and patients for whom informed consent was
not obtained. The medical ethics committee of
Erasmus University and University Hospital Rotter›
dam approved the trial protocol.
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The general practitioner notified the research
nurse of suitable patients, and the nurse visited the
children at home, usually the same day. The nurse
recorded the duration of impetigo, nature of the
lesions (redness, crusts, pustules, and painfulness),
number of lesions, localisation and estimated area of
lesions, body temperature, presence of regional
lymphadenopathy, recent use of antibiotics, demo›
graphic data, and pre›existence of eczema. After
obtaining written informed consent, the nurse took a
bacterial swab of the lesions and started the treatment.
Interventions
The lesions were washed gently with povidone›iodine
shampoo (Betadine shampoo; ASTA, Diemen, Nether›
lands), 75 mg/ml twice daily, in the morning and the
evening. The study cream was applied three times a day
(once after each shampoo and once at midday). The
study cream was either 2% fusidic acid cream (Fucidin;
Leo Pharmaceutical Products BV, Weesp, Netherlands)
or placebo cream containing 13.5 g vaseline›
cetomacrogol cream, 8.25 g glycerol 85%, 0.03 g sorbic
acid, and distilled water up to 30 g. Patients were
advised to use the study cream for a maximum of 14
days or until the lesions had disappeared and to use
common hygienic measures (cutting nails short, use of
personal towels).
The research nurse visited participants at home for
evaluation at 7, 14, and 28 days after the start of treat›
ment and recorded data on clinical cure, compliance,
use of other drugs, violation of the protocol, and side
effects. The nurse took a swab for bacterial culture of
the lesions if they were still present. General practition›
ers were free to prescribe other treatment such as oral
antibiotics if the impetigo worsened or did not
improve, but they were encouraged to comply with the
study protocol for at least the first week. When patients
withdrew from the protocol regimen, the evaluation
visits were carried out as planned.
Assignment and masking
The placebo cream, prepared by the pharmacist, did
not differ in colour, smell, or consistency from the
fusidic acid cream. An independent statistician
provided a computer generated list of random set
numbers in permuted blocks of six. The hospital phar›
macist packed the study medication in identical blank
tubes with a code number according to the
randomisation list. We randomised the patients in
blocks and stratified them for presence of pre›existing
eczema at the site of the impetigo. The research nurse,
who was unaware of the treatment allocation, allocated
patients to the first available number of study cream in
the corresponding block. The pharmacist kept the list
of code numbers in a sealed envelope and was not
involved in analysis of data or assessment of outcome.
Unblinding took place after the primary statistical
analysis had been done.
Outcomes
Primary outcome measures were clinical cure,
improvement, and size of affected area, as assessed by
the research nurse, and bacterial cure after 7, 14, and
28 days. We defined clinical cure as the complete
absence of lesions or the lesions having become dry
and without crusts; remaining local redness of intact
skin was acceptable. In cases of incomplete cure the
nurse recorded the number, localisation, and size of the
affected area of the persisting lesions. The size of the
affected area was estimated by comparing the size of
the actual lesions with a range of examples with differ›
ent exactly measured areas on paper. We defined
improvement as a decline in affected area, number of
lesions, or both. We defined bacterial cure as the elimi›
nation of the causative pathogen(s) in persisting lesions
or the unavailability of a swab if lesions were cured.
Adverse effects were secondary outcome measures. We
considered baseline characteristics, causative patho›
gen, and resistance of the pathogen to fusidic acid at
baseline as possible confounding factors.
Microbiological procedures
The nurse used sterile cotton wool swabs (Transwab;
Medical Wire and Equipment, Corsham, UK) to obtain
swab specimens of the wound. The largest five lesions
were swabbed with one swab by gently rubbing the
wound surface. The swabs were immediately placed in
Stuart’s transport medium and kept at 4°C until inocu›
lation (within 24 hours). We cultured the swabs
semiquantitatively on Columbia blood agar plates
(Becton›Dickinson, Etten›Leur, Netherlands), which
were incubated anaerobically; phenol red mannitol salt
agar; and phenol red mannitol salt broth.18 We
identified bacteria according to accepted international
standards, on the basis of morphology of colonies on
the Columbia blood agar and phenol red mannitol salt
agar.19 Suspected colonies were cultured overnight on
Columbia blood agar. We then did a catalase test and a
latex agglutination test (Staphaurex Plus; Murex, Dart›
ford, UK). We used antisera to the Lancefield groups A,
B, C, F, and G cell wall carbohydrates (PathoDx, Strep
Grouping latex agglutination kit; DPC, Los Angeles,
CA) to identify â haemolytic streptococci. All isolates
were stored at − 70°C in liquid media containing glyc›
erol. We used Vitek II equipment (bioMerieux Vitek,
Hazelwood, MO) for susceptibility testing of isolates of
S aureus. We used disk diffusion to test for susceptibility
to mupirocin.20 The panel of antibiotics for staphy›
lococci consisted of erythromycin, fusidic acid, and
mupirocin. We used the guidelines of the National
Committee for Clinical Laboratory Standards to
categorise strains as resistant, intermediately sensitive,
or sensitive to the antibiotic used.21 22
Statistical analysis
We analysed the results both by intention to treat and
per protocol. We used logistic regression analysis to
calculated crude and adjusted odds ratios for dichoto›
mous outcome measures. Baseline characteristics that
had at least a weak relation (P < 0.25) with the outcome
variable in univariate logistic regression analyses were
considered to be potentially adjusting variables. If con›
tinuous baseline characteristics showed a non›linear
relation with the outcome variable, we transformed
these into categorical variables with two or three levels.
We used a forward selection procedure (Wald) to
determine which adjusting variables entered the final
multivariate model. For the change in affected area—a
continuous outcome—we used linear regression analy›
sis, with the logarithm of the ratio of the area of the
lesions at three visits and the area at baseline as
dependent variables. With a postulated spontaneous
cure of 50% at one week and a detectable absolute dif›
ference of 25% in the treatment group, with á = 0.05
Primary care
2 BMJ VOLUME 324 26 JANUARY 2002 bmj.com
and â = 0.10, the planned study population was 85
children in each group.
Results
From February 1999 to November 2000, 58 general
practitioners reported 184 children with impetigo.
After the inclusion visit of the research nurse, 160 chil›
dren were included and randomised (fig). The groups
were comparable with respect to baseline characteris›
tics (table 1). Non›Dutch patients were mainly of Turk›
ish or Moroccan origin, reflecting the distribution of
the population in the catchment area.
As the number of missing evaluation visits was very
small and was similar in the two groups (fig), we
decided not to impute data but to exclude these
children from the analysis for that particular
evaluation moment.
For the intention to treat analysis the proportion of
children cured clinically at one week was 55% in the
fusidic acid cream group and 13% in the placebo
group, resulting in a number needed to treat of 2.3. At
two weeks and four weeks the results were still in favour
of fusidic acid, but the differences were smaller and the
results were no longer significant (tables 2 and 3). The
final multivariate model contained, apart from
treatment, the size of the affected area (adjusted odds
ratio 12.6, 95% confidence interval 5.0 to 31.5). Clinical
improvement and cure combined yielded a crude odds
ratio of 5.2 (fusidic acid v placebo); this hardly changed
after adjustment. The mean affected area declined
steadily in the fusidic acid group, whereas in the
placebo group the mean affected area had increased
after one week’s treatment (table 4). No difference was
found between children with and without eczema
(results not shown).
Non›compliance
In the first week, three patients in the fusidic acid cream
group and eight patients in the placebo group did not
comply with the treatment protocol. Nine patients,
seven of whom were in the placebo group, had
received an antibiotic treatment from their general
practitioner and stopped using the study cream, in
most cases because the impetigo had worsened or had
not improved. Two patients, one in each group, had
stopped using the study cream before the impetigo was
cured but had not used any other treatment. Minor
violations of the protocol, such as omission of a single
Children reported and visited (n=184)
Excluded (n=24)
  No impetigo present (n=5)
  Too old (n=4)
  Recent antibiotic use (n=6)
  Fever (n=2)
  No informed consent (n=7)
Assigned povidone-iodine
 and fusidic acid cream; all
 received intervention (n=78)
1 week
Discontinued intervention (n=3)
  Received antibiotic (n=2)
  Stopped using cream (n=1)
76 analysed
Lost to follow up:
 Did not want to
 continue treatment
 or evaluation (n=2)
Assigned povidone-iodine
 and placebo cream; all
 received intervention (n=82)
Children randomised (n=160)
2 weeks
Discontinued intervention (n=2)
  Received antibiotic (n=1)
  Stopped using cream (n=1)
No evaluation visit (n=4)
72 analysed
4 weeks
76 analysed
1 week
Discontinued intervention (n=8)
  Received antibiotic (n=7)
  Stopped using cream (n=1)
80 analysed
Lost to follow up:
 Did not want to
 continue treatment
 or evaluation (n=2)
2 weeks
Discontinued intervention (n=4)
  Received antibiotic (n=4)
No evaluation visit (n=3)
77 analysed
4 weeks
No evaluation visit (n=2)
78 analysed
Flow and follow up of participants
Table 1 Baseline characteristics of study population (n=160).
Values are numbers (percentages) unless stated otherwise
Fusidic acid cream
(n=78)
Placebo cream
(n=82)
Mean (SD) age (years) 4.8 (2.9) 5.1 (2.7)
Boys 47 (60) 51 (62)
Dutch origin 47 (60) 48 (59)
Attending day care or school 59 (76) 66 (80)
Mean (SD) No of lesions 11.4 (13.3) 13.2 (14.5)
Mean (SD) affected area (cm2) 5.6 (7.3) 7.3 (11.4)
Mean (SD) body temperature (°C) 36.5 (0.7) 36.6 (0.7)
Lymphadenopathy 32 (41) 25 (30)
Mean (SD) duration of impetigo (days) 9.6 (8.0) 9.2 (10.2)
Localisation:
Head 61 (78) 61 (74)
Trunk 22 (28) 29 (35)
Limbs 36 (46) 33 (40)
Pre›existing eczema 10 (13) 12 (15)
Pathogen isolated:
Staphylococcus aureus 66 (85) 61 (74)
Streptococcus pyogenes (A) 1 (1) 4 (5)
Both 1 (1) 7 (9)
None 10 (13) 10 (12)
Fusidic acid resistance (S aureus):
Resistant 0/67 (0) 0/68 (0)
Intermediately sensitive 3/67 (4) 7/68 (10)
Sensitive 64/67 (96) 61/68 (90)
Mupirocin resistance (S aureus) 1/67 (1) 0/68 (0)
Erythromycin resistance (S aureus) 6/67 (9) 8/68 (12)
Table 2 Clinical effect and bacterial cure (intention to treat
analysis). Values are numbers (percentages)
Fusidic acid cream (n=76) Placebo cream (n=80)
One week
Clinical effect:
Cure 42/76 (55) 10/80 (13)
Improvement 25/76 (32) 37/80 (46)
Failure 9/76 (11) 33/80 (41)
Bacterial cure 63/69 (91) 23/72 (32)
Two weeks
Clinical effect:
Cure 53/72 (73) 46/77 (60)
Improvement 17/72 (23) 20/77 (26)
Failure 2/72 (3) 11/77 (14)
Bacterial cure 62/70 (89) 52/70 (74)
Four weeks
Clinical effect:
Cure 70/76 (92) 69/78 (88)
Improvement 5/76 (7) 7/78 (9)
Failure 1/76 (1) 2/78 (3)
Bacterial cure 71/75 (95) 70/75 (93)
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application of povidone›iodine shampoo or study
cream, were recorded in 14 cases (not shown in table).
Another six patients were non›compliant in the second
week (four in the placebo group and two in the fusidic
acid group) and another five patients received extra
antibiotic treatment—four patients in the placebo
group and one in the fusidic acid group.
Side effects
Side effects were experienced in 26 cases—seven
occurred in the fusidic acid group and 19 in the
placebo group. The most frequent side effects were
pain (two in the fusidic acid group v six in the placebo
group) and burning (one v four) during administration
of the povidone›iodine shampoo. Other side effects
were redness (two in each group), burning from the
study cream (one in placebo group), itching from both
applications (two in placebo group), and pain and irri›
tation from both applications (one in each group).
Bacteriological results
For all the baseline visits and 431 (94%) of the 459 fol›
low up visits, swabs were available or lesions were
cured. S aureus was found in 135 (96%) of the 140 posi›
tive cultures at baseline (table 1); S pyogenes and mixed
infections were found in a minority of cases. No strain
of staphylococcus was found to be resistant to fusidic
acid. Ten of the 140 strains were intermediately
sensitive to fusidic acid. At baseline, 20 (12.5%) of the
160 swab cultures showed no bacterial growth. In the
intention to treat analysis, the proportion of children
with bacterial cure at one week was 91% in the fusidic
acid group compared with 32% in the placebo group
(tables 2 and 5).
Discussion
This is the first study to compare fusidic acid cream with
placebo in treating impetigo. It shows that application of
fusidic acid cream in combination with povidone›iodine
shampoo is much more effective than placebo cream
combined with povidone›iodine shampoo.
The treatment effect of fusidic acid cream
compared with placebo after one week was even larger
after adjustment for potential confounders. After two
and four weeks the differences between the two
treatments were smaller and no longer significant. If it
was not due to the possibly benign spontaneous course
of impetigo, this finding was probably caused by the
fact that more patients in the placebo group had
“crossover treatment” with antibiotics. Fourteen per
cent of the patients in the placebo group compared
with 4% in the fusidic acid group returned to their
general practitioner because of failure of treatment
and received an extra, usually oral, antibiotic treatment.
Our hypothesis that fusidic acid cream would not
increase the treatment effect of disinfecting with
povidone›iodine is firmly rejected. The results do not
support conservative treatment with disinfecting meas›
ures alone. Treatment with povidone›iodine combined
with placebo cream had a very disappointing cure rate
of 13% at one week. The mean affected area after one
week of treatment was even larger than at the start of
treatment. Also, administration of the povidone›iodine
more often caused pain and burning in the placebo
group, which may be explained by prolonged healing
of the lesions in this group. The low cure rates in this
study and the reported side effects raise questions
about the value of povidone›iodine as an adjunctive
treatment for impetigo. Doubts have already been
raised about the value of other disinfecting measures in
the treatment of impetigo.6 23 24 Future studies compar›
ing povidone›iodine with placebo may provide more
evidence.
A small number of swab results (12.5%) were nega›
tive at baseline—because we were studying patients
with a clinical diagnosis of impetigo we had no reason
to exclude these patients. S aureus was the pathogen
most often found, which accords with other investiga›
tions showing that the predominant organism in
impetigo has changed from S pyogenes to S aureus in
recent years.1 11 We did not find resistance to fusidic
acid in our study population, indicating that many
years of use of topical fusidic acid has not resulted in
appreciable resistance in staphylococci in the general
population. The resistance to erythromycin in staphy›
lococci was higher, in accordance with the inter›
national trend. Although oral antibiotics are used for
impetigo in many countries, this finding provides an
extra argument for topical treatment with fusidic acid
cream.
Our recent meta›analysis showed that fusidic acid
and mupirocin were equally effective in treating
impetigo,17 but fusidic acid costs less. Regional
antibiotic policies may differ in restricting the use of
one of these two antibiotics.3 5 16
Table 3 Clinical cure: results of logistic regression analysis. Odds ratios (95% CI)
fusidic acid cream (F) versus placebo (P)
Intention to treat analysis Per protocol analysis
Cured Cured or improved Cured Cured or improved
One week: (F, n=76; P, n=80) (F, n=73; P, n=72)
Crude 8.7 (3.9 to 19.3) 5.2 (2.3 to 11.9) 8.5 (3.6 to 19.1) 5.2 (2.2 to 12.4)
Adjusted 12.6 (5.0 to 31.5) 5.5 (2.3 to 13.4) 3.0 (5.0 to 33.8) 5.2 (2.2 to 12.4)
Two weeks: (F, n=72; P, n=77) (F, n=68; P, n=65)
Crude 1.9 (0.9 to 3.8) 5.8 (1.2 to 27.3) 1.8 (0.8 to 3.6) 4.6 (0.9 to 22.7)
Adjusted 1.9 (0.8 to 4.1) 5.2 (1.1 to 24.9) 1.9 (0.8 to 4.7) 4.1 (0.8 to 21.9)
Four weeks: (F, n=76; P, n=78) (F, n=71; P, n=66)
Crude 1.5 (0.5 to 4.5) 2.0 (0.2 to 22.2) 1.1 (0.3 to 3.5) 1.1 (0.1 to 17.6)
Adjusted 1.8 (0.5 to 5.9) 2.3 (0.1 to 50.5) 1.1 (0.3 to 3.7) 1.7 (0.0 to 26.6)
Table 4 Mean change in size of affected area. Affected area at
baseline=100%
Fusidic acid
cream
Placebo
cream
Adjusted P value (intention to
treat analysis)
One week −66% 27% <0.001
Two weeks −90% −38% 0.24
Four weeks −99% −95% 0.67
Table 5 Bacterial cure: results of logistic regression analysis.
Odds ratios (95% CI) fusidic acid cream (F) versus placebo (P)
Intention to treat analysis Per protocol analysis
One week: (F, n=69; P, n=72) (F, n=70; P, n=63P)
Crude 22.4 (8.5 to 59.2) 23.9 (8.4 to 68.0)
Adjusted 28.3 (9.5 to 84.7) 43.9 (13.1 to 147.1)
Two weeks: (F, n=70; P, n=70) (F, n=66; P, n=58)
Crude 2.7 (1.1 to 6.7) 2.4 (0.9 to 6.6)
Adjusted 2.9 (1.1 to 7.8) 2.8 (0.9 to 8.1)
Four weeks: (F, n=75; P, n=75) (F, n=70; P, n=63)
Crude 1.3 (0.3 to 4.9) 0.5 (0.1 to 3.1)
Adjusted 1.1 (0.3 to 4.4) 0.4 (0.1 to 2.7)
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We conclude that topical fusidic acid cream is an
effective treatment for impetigo, with very few side
effects, and can be considered a first choice in the treat›
ment of impetigo in general practice. The value of sole
or adjunctive treatment with povidone›iodine can be
questioned.
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What is already known on this topic
Impetigo is the most common skin infection in
children
Fusidic acid, which is advocated as topical
treatment in several countries, has never been
investigated in a placebo controlled study
What this study adds
In combination with povidone›iodine, treatment
with fusidic acid is much more effective than
placebo
None of the strains of Staphylococcus aureus isolated
at baseline showed resistance to fusidic acid
The value of treatment with povidone›iodine
alone can be questioned
Primary care
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